{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:19:15Z","timestamp":1785449955061,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.amjmed.2019.05.021","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T23:14:13Z","timestamp":1559171653000},"page":"e827-e834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Eosinopenia as an Adverse Marker of Clinical Outcomes in Patients Presenting with Acute Myocardial Infarction"],"prefix":"10.1016","volume":"132","author":[{"given":"Mohammad","family":"Alkhalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Hegarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peadar","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colum G.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Spence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2019.05.021_bb0005","first-page":"119","volume":"39","author":"The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","year":"2017","journal-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 2018"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/ehjcvp\/pvw034","article-title":"Plaque imaging to refine indications for emerging lipid-lowering drugs","volume":"3","author":"Alkhalil","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/eht398","article-title":"Targeting inflammatory pathways for the treatment of cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0030","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Cantos Trial Group","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042860","article-title":"Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study","volume":"7","author":"Terradas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0045","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/eji.201646557","article-title":"Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart","volume":"46","author":"Diny","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0050","doi-asserted-by":"crossref","first-page":"A152","DOI":"10.1136\/heartjnl-2017-311726.236","article-title":"Eosinophils have an essential role in cardiac repair following myocardial infarction","volume":"103","author":"Toor","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0055","first-page":"1265","article-title":"Eosinopenia of acute infection","volume":"65","author":"Bass","year":"1980","journal-title":"Production of eosinopenia by chemotactic factors of acute inflammation J Clin Invest"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1440-1843.2009.01651.x","article-title":"Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease","volume":"15","author":"Holland","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001956","article-title":"Systemic atherosclerotic inflammation following acute myocardial infarction: myocardial infarction begets myocardial infarction","volume":"4","author":"Joshi","year":"2015","journal-title":"J American Heart Association"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0070","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206344","article-title":"Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion","volume":"13","author":"Rios-Navarro","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0080","first-page":"962","article-title":"Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction","volume":"47","author":"Suleiman","year":"2006","journal-title":"predictive role of C-reactive protein J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0085","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1053\/euhj.2001.2988","article-title":"The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty","volume":"23","author":"de Winter","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0090","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0095","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0100","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"JUPITER Trial Study Group","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0105","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"Investigators","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0110","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2016.07.768","article-title":"Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance","volume":"68","author":"Choudhury","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"ATLAS ACS TIMI Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0120","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0125","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Investigators","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0130","first-page":"752","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"CIRT Investigators","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0135","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.12.007","article-title":"Eosinopenia as a predictive factor of the short-term risk of mortality and infection after acute cerebral infarction","volume":"25","author":"Hori","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.amjmed.2019.05.021_bb0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.5551\/jat.37937","article-title":"Prognostic value of eosinophil to leukocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"24","author":"Konishi","year":"2017","journal-title":"J Atheroscler Thromb"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319304577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319304577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:19:18Z","timestamp":1757582358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934319304577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0002934319304577"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.05.021","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinopenia as an Adverse Marker of Clinical Outcomes in Patients Presenting with Acute Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}